Price predictions, page-58

I think we need to be mindful though that Qbrexza didn't sell in Japan previously, which is supposed to be BOT's closest competitor in the US.

Also, Qbrexza only sold $25m in the US last FY, so it would seem that even though Ecclock did well in Japan, it does seem BOT are expecting quite a take-up of SB in the US. I'm not sure their $100m is realistic. Don't get me wrong, I would love it to be $100m turnover within a year, but I expect that is years and years down the track.

Then again, maybe Qbrexza is an absolutely crap product in the hyperhidrosis world and we'll see SB sold at record levels.